Latest period
$6.45B
YoY change
-30.3%
5Y CAGR
-20.0%
Peak year (2020)
$9.67B
Latest annual
$3.17B
Free Cash Flow history chart for Elevance Health (ELV) from 2001 to 2025
Latest: $3.17B
Free Cash Flow growth chart for Elevance Health (ELV) from 2001 to 2025
Latest: -30.3%
Free Cash Flow history table for Elevance Health (ELV) from 2001 to 2025
| 2025 | $3.17B | -30.3% | −$1.38B | ||
| 2024 | $4.55B | -32.7% | −$2.21B | ||
| 2023 | $6.76B | -6.7% | −$482.00M | ||
| 2022 | $7.25B | -0.4% | −$30.00M | ||
| 2021 | $7.28B | -24.7% | −$2.39B | ||
| 2020 | $9.67B | +94.0% | +$4.68B | ||
| 2019 | $4.98B | +90.3% | +$2.37B | ||
| 2018 | $2.62B | -22.8% | −$775.60M | ||
| 2017 | $3.39B | +29.5% | +$773.70M | ||
| 2016 | $2.62B | -25.4% | −$892.20M | ||
| 2015 | $3.51B | +28.1% | +$770.40M | ||
| 2014 | $2.74B | +12.2% | +$297.70M | ||
| 2013 | $2.44B | +11.2% | +$245.30M | ||
| 2012 | $2.20B | -23.0% | −$655.20M | ||
| 2011 | $2.85B | +195.8% | +$1.89B | ||
| 2010 | $965.30M | -63.7% | −$1.70B | ||
| 2009 | $2.66B | +21.5% | +$470.70M | ||
| 2008 | $2.19B | -45.6% | −$1.83B | ||
| 2007 | $4.02B | +4.5% | +$172.30M | ||
| 2006 | $3.85B | +24.4% | +$755.40M | ||
| 2005 | $3.09B | +165.3% | +$1.93B | ||
| 2004 | $1.17B | +12.9% | +$133.70M | ||
| 2003 | $1.03B | +19.0% | +$164.90M | ||
| 2002 | $867.80M | +48.5% | +$283.60M | ||
| 2001 | $584.20M | — | — |
- 2025$3.17B-30.3%
- 2024$4.55B-32.7%
- 2023$6.76B-6.7%
- 2022$7.25B-0.4%
- 2021$7.28B-24.7%
- 2020$9.67B+94.0%
- 2019$4.98B+90.3%
- 2018$2.62B-22.8%
- 2017$3.39B+29.5%
- 2016$2.62B-25.4%
- 2015$3.51B+28.1%
- 2014$2.74B+12.2%
- 2013$2.44B+11.2%
- 2012$2.20B-23.0%
- 2011$2.85B+195.8%
- 2010$965.30M-63.7%
- 2009$2.66B+21.5%
- 2008$2.19B-45.6%
- 2007$4.02B+4.5%
- 2006$3.85B+24.4%
- 2005$3.09B+165.3%
- 2004$1.17B+12.9%
- 2003$1.03B+19.0%
- 2002$867.80M+48.5%
- 2001$584.20M—
Free Cash Flow values are taken from Elevance Health's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Elevance Health (ELV)
Free Cash Flow for Elevance Health (ELV): headline value $6.45B · YoY -30.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Elevance Health (ELV) reported free cash flow of $3.17B – plunged 30.3% year-over-year.
Through 2020–2025 (5 years), Elevance Health free cash flow delivered a -20.0% annualised rate; with a net decline across the window.
Elevance Health free cash flow peaked at $9.67B in 2020; the latest annual figure is $3.17B in 2025 (67.2% below peak).
Across the available history, free cash flow reached its high of $9.67B in 2020 and its low of $584.20M in 2001.
Elevance Health Free Cash Flow by Year
Elevance Health Free Cash Flow 2025: $3.17B
In 2025, Elevance Health reported free cash flow of $3.17B, plunged 30.3% below 2024.
Elevance Health Free Cash Flow 2024: $4.55B
Elevance Health free cash flow in 2024 was $4.55B, plunged 32.7% below 2023.
Elevance Health Free Cash Flow 2023: $6.76B
2023's free cash flow for Elevance Health came in at $6.76B, declined 6.7% below 2022.
Elevance Health Free Cash Flow 2022: $7.25B
Elevance Health posted free cash flow of $7.25B in 2022, edged down 0.4% below 2021.
Elevance Health Free Cash Flow 2021: $7.28B
Elevance Health free cash flow in 2021 was $7.28B.
See more financial history for Elevance Health (ELV).
Sector peers by Free Cash Flow
Healthcare peers of Elevance Health (ELV), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $8.97B | |
| $8.67B | |
| $8.10B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $8.97B
- $8.67B
- $8.10B
- $4.52B
Frequently asked questions
Elevance Health (ELV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation